1 week ago
ImmunityBio (IBRX) Stock Falls 18% Despite Cancer Trial Win and 92% Sales Growth
TLDR IBRX stock fell about 18% on Monday after a busy round of company news. Q3 net product revenue hit $48.7 million, up 53%, and nine-month revenue rose 92% to $143.6 million. ANKTIVA plus BCG met its primary goal in Cohort A of the QUILT-2.005 trial. Q3 net loss to common stockholders grew to $184.6 [...]
The post ImmunityBio (IBRX) Stock Falls 18% Despite Cancer Trial Win and 92% Sales Growth appeared first on Blockonomi.
Source: Blockonomi →Related News
- 41 minutes ago
Nvidia tops estimates, issues strong guidance; shares rise
- 41 minutes ago
Microsoft Corporation (MSFT) Stock: Fall 2.37% Despite Major AI Security Initia...
- 1 hour ago
KIDZ AI Inc. (KIDZ) Stock: Eyes Growth Through Synestria GPU Computing Partnersh...
- 1 hour ago
Vertiv Holdings (VRT) Stock: Expands 800 VDC Power Systems for AI Data Centers
- 2 hours ago
Coinbase CEO says AI agents will account for '99.9%' of transactions within a de...
